Equities Analysts Offer Predictions for IONS Q1 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Ionis Pharmaceuticals in a note issued to investors on Monday, April 7th. HC Wainwright analyst M. Kapoor expects that the company will earn ($1.04) per share for the quarter. HC Wainwright has a “Strong-Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. HC Wainwright also issued estimates for Ionis Pharmaceuticals’ Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.61) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.86) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.46. The company had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. Ionis Pharmaceuticals’s revenue was down 30.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.12 earnings per share.

IONS has been the subject of several other research reports. William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a research report on Tuesday. JPMorgan Chase & Co. lowered their price target on Ionis Pharmaceuticals from $47.00 to $45.00 and set a “neutral” rating for the company in a report on Monday, March 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday, February 20th. Finally, Redburn Atlantic began coverage on Ionis Pharmaceuticals in a research note on Monday, March 31st. They issued a “neutral” rating and a $39.00 price target for the company. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $56.79.

Ionis Pharmaceuticals Stock Up 8.9 %

IONS opened at $27.77 on Thursday. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. The firm has a market cap of $4.41 billion, a P/E ratio of -9.13 and a beta of 0.29. The business’s fifty day simple moving average is $31.41 and its 200 day simple moving average is $34.80. Ionis Pharmaceuticals has a 52 week low of $23.95 and a 52 week high of $52.34.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Signaturefd LLC increased its position in Ionis Pharmaceuticals by 160.0% in the 4th quarter. Signaturefd LLC now owns 949 shares of the company’s stock worth $33,000 after purchasing an additional 584 shares during the last quarter. Huntington National Bank increased its position in Ionis Pharmaceuticals by 193.5% in the 4th quarter. Huntington National Bank now owns 951 shares of the company’s stock worth $33,000 after purchasing an additional 627 shares during the last quarter. Lindbrook Capital LLC increased its holdings in shares of Ionis Pharmaceuticals by 183.8% during the 4th quarter. Lindbrook Capital LLC now owns 1,036 shares of the company’s stock valued at $36,000 after acquiring an additional 671 shares during the last quarter. Raiffeisen Bank International AG acquired a new position in shares of Ionis Pharmaceuticals during the 4th quarter valued at about $62,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Ionis Pharmaceuticals during the 4th quarter valued at about $107,000. 93.86% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Brett P. Monia sold 33,445 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.63, for a total transaction of $1,091,310.35. Following the transaction, the chief executive officer now directly owns 207,396 shares of the company’s stock, valued at approximately $6,767,331.48. The trade was a 13.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Eric Swayze sold 7,154 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $32.84, for a total value of $234,937.36. Following the transaction, the executive vice president now directly owns 45,670 shares in the company, valued at $1,499,802.80. The trade was a 13.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 111,956 shares of company stock valued at $3,608,439 over the last three months. Insiders own 2.71% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.